These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 8857563)
1. Clinical development of a cyclosporine microemulsion in transplantation. Kovarik JM; Mueller EA; Niese D Ther Drug Monit; 1996 Aug; 18(4):429-34. PubMed ID: 8857563 [TBL] [Abstract][Full Text] [Related]
2. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period. Wahlberg J; Wilczek HE; Fauchald P; Nordal KP; Heaf JG; Olgaard K; Hansen JM; Lokkegaard H; Mueller EA; Kovarik JM Transplantation; 1995 Oct; 60(7):648-52. PubMed ID: 7570970 [TBL] [Abstract][Full Text] [Related]
3. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P; Niese D Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620 [TBL] [Abstract][Full Text] [Related]
4. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473 [TBL] [Abstract][Full Text] [Related]
5. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Coukell AJ; Plosker GL Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420 [TBL] [Abstract][Full Text] [Related]
6. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
7. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Ritschel WA Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110 [TBL] [Abstract][Full Text] [Related]
8. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group. Pollard SG; Lear PA; Ready AR; Moore RH; Johnson RW Transplantation; 1999 Nov; 68(9):1325-31. PubMed ID: 10573071 [TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Taesch S; Niese D Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220 [TBL] [Abstract][Full Text] [Related]
11. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. Otto MG; Mayer AD; Clavien PA; Cavallari A; Gunawardena KA; Mueller EA Transplantation; 1998 Dec; 66(12):1632-40. PubMed ID: 9884251 [TBL] [Abstract][Full Text] [Related]
12. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related]
13. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S; Markham A Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [TBL] [Abstract][Full Text] [Related]
14. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics. Anderson IF; Helve T; Hannonen P; Leirisalo-Repo M; Gilboe IM; Nissilä M; Keystone EC; Kraag GR; Bjørneboe O; Chalmers A; Dovland H; Mueller E; Richard F; Whatmough I; Schmidt AG; Kovarik JM J Rheumatol; 1999 Mar; 26(3):556-62. PubMed ID: 10090162 [TBL] [Abstract][Full Text] [Related]
15. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation]. Humbert H Therapie; 1997; 52(4):353-7. PubMed ID: 9437891 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766 [TBL] [Abstract][Full Text] [Related]
17. Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients. Kovarik JM; Mueller EA; van Bree JB; Flückiger SS; Lange H; Schmidt B; Boesken WH; Lison AE; Kutz K Transplantation; 1994 Sep; 58(6):658-63. PubMed ID: 7940685 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation. Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343 [TBL] [Abstract][Full Text] [Related]
19. The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts. Khajehdehi P; Yip D; Bastani B Clin Transplant; 1999 Apr; 13(2):176-80. PubMed ID: 10202614 [TBL] [Abstract][Full Text] [Related]
20. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]